About CARB-X
CARB-X is a company based in Boston (United States) founded in 2016. CARB-X offers products and services including Funding Program and Portfolio Acceleration Tools. CARB-X operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Wellcome
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CARB-X
CARB-X offers a comprehensive portfolio of products and services, including Funding Program and Portfolio Acceleration Tools.
Provides grants for antibacterial research projects.
Offers resources for advancing drug development initiatives.
People of CARB-X
Unlock access to complete
Funding Insights of CARB-X
Investors in CARB-X
CARB-X has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wellcome and BARDA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health research and advocacy are funded globally by the foundation.
|
Locked | Locked | Locked | |
|
BARDA is focused on developing medical countermeasures for public health security.
|
Locked | Locked | Locked |
Investor details for CARB-X
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CARB-X
Investment portfolio details for CARB-X
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CARB-X
Detailed financials for CARB-X
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carb-X Comparisons
Peer comparison for CARB-X
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CARB-X
CARB-X operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Pharmaceuticals for acute care bacterial infections are developed and commercialized.
|
Detailed competitors of CARB-X
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carb-X
Complete news archive for CARB-X
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CARB-X
CARB-X was founded in 2016 and raised its 1st funding round 6 years after it was founded.
CARB-X is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
CARB-X was founded in 2016 and is based in Boston, United States. Antibiotics targeting drug-resistant bacteria are developed by the organization, alongside vaccines and rapid diagnostics. These initiatives are advanced through clinical trial phases within the biotechnology sector. Operations emphasize solutions for antimicrobial resistance, supporting global health efforts in infectious disease management.
CARB-X's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
CARB-X offers Funding Program and Portfolio Acceleration Tools.